ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00729404
Recruitment Status : Terminated
First Posted : August 7, 2008
Last Update Posted : December 2, 2014
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
Investigation of two transdermal hormone patch formulations for contraception regarding inhibition of ovulation over a period of 3 treatment cycles in healthy young female volunteers

Condition or disease Intervention/treatment Phase
Contraception Ovulation Inhibition Drug: Ethinylestradiol/Gestodene (BAY86-5016) Phase 2

Detailed Description:
Study was suspended due to inconclusive toxicology findings regarding the used patch formulation to be clarified prior to re-start of the study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Open-label, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg EE and Either 1.05 or 2.1 mg GSD in Healthy Young Female Vol. Over a Period of 3 Treatment Cycles
Study Start Date : August 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birth Control
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Arm 1 Drug: Ethinylestradiol/Gestodene (BAY86-5016)
transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
Experimental: Arm 2 Drug: Ethinylestradiol/Gestodene (BAY86-5016)
transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles



Primary Outcome Measures :
  1. The primary efficacy variable will be the proportion of volunteers with ovulation in at least one of the treatment cycles 2 and 3. [ Time Frame: 4 month ]

Secondary Outcome Measures :
  1. Assessment of ovarian activity during treatment cycle2 and 3 (Hoogland score) [ Time Frame: 4 month ]
  2. Course of gonadotropins (FSH, LH, P, E2) [ Time Frame: 4 month ]
  3. Endometrial thickness [ Time Frame: 4 month ]
  4. Follicle size [ Time Frame: 4 month ]
  5. Pharmacokinetics of EE, GSD and SHBG in treatment cycles 2 and 3 [ Time Frame: 4 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Signed informed consent,
  • BMI: 18 - 30 kg/m²,
  • Healthy female volunteers,
  • Age 18-35 years (smoker not older than 30 years, inclusive),
  • Ovulatory pre-treatment cycle, at least 3 month since delivery,
  • Abortion or lactation before the first screening examination,
  • Willingness to use non-hormonal methods of contraception during entire study

Exclusion Criteria:

  • Contraindications for use of combined (estrogen/gestodene) contraceptive (e.g. history of venous/arterial thromboembolic disease
  • Regular intake of medication other than OCs
  • Clinically relevant findings (blood pressure, physical and gynaecological examination, laboratory examination)
  • Anovulatory pre-treatment cycle

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00729404


Locations
Germany
Berlin, Germany, 10115
Berlin, Germany, 10707
Berlin, Germany, 13342
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00729404     History of Changes
Other Study ID Numbers: 91558
2008-001198-13 ( EudraCT Number )
First Posted: August 7, 2008    Key Record Dates
Last Update Posted: December 2, 2014
Last Verified: November 2014

Keywords provided by Bayer:
Female Contraception
Ovulation Inhibition

Additional relevant MeSH terms:
Ethinyl Estradiol
Gestodene
Femovan
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Progestins
Contraceptives, Oral, Combined